Риоцигуат - новый препарат для лечения легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии
https://doi.org/10.21518/2079-701X-2016-4-20-27
Аннотация
Ключевые слова
Об авторах
Н. А. ЦареваРоссия
С. Н. Авдеев
Россия
Список литературы
1. Чазова И.Е., Мартынюк Т.В. (ред.). Легочная гипертензия. М.: Практика. 2015: 55-103.
2. Brendan Madden (ed). Treatment of Pulmonary Hypertension. Current Cardiovascular Therapy. Springer International Publishing Switzerland 2015. DOI 10.1007/978-3-319-13581-6. ISBN 978-3-319-13581-6.
3. Чазова И.Е., Мартынюк Т.В., Авдеев С.Н., Волков А.В., Наконечников С.Н. Клинические рекомендации по диагностике и лечению легочной гипертензии. Евразийский кардиологический журнал, 2014, 4: 4-23.
4. GaLie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et aL. 2015 ESC/ERS Guidelines for the diagnosis and treatment of puLmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of PuLmonary Hypertension of the European Society of CardioLogy (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and CongenitaL CardioLogy (AEPC), InternationaL Society for Heart and Lung TranspLantation (ISHLT). Eur Heart J, 2016, 37: 67-119.
5. GaLie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et aL. 2015 ESC/ERS Guidelines for the diagnosis and treatment of puLmonary hypertension - web addenda: The Joint Task Force for the Diagnosis and Treatment of PuLmonary Hypertension of the European Society of CardioLogy (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and CongenitaL CardioLogy (AEPC), InternationaL Society for Heart and Lung TranspLantation (ISHLT). European Heart Journal. AvaiLabLe at: http://www.escardio.org/GuideLines-&-Education/CLinicaL-Practice-GuideLines/ PuLmonary-Hypertension-GuideLines-on-Diagnosis-and-Treatment-of.
6. Ghofrani HA et aL. Riociguat for the Treatment of PuLmonary ArteriaL Hypertension. N Engl J Med, 2013, 369: 330-40. (DOI: 10.1056/NEJMoa1209655) + ProtocoL + SuppLementary appendix.
7. Ghofrani HA, et aL. Riociguat for the Treatment of Chronic ThromboemboLic PuLmonary Hypertension. N Engl J Med, 2013, 369: 319-29.
8. Царева Н.А., Авдеев С.Н., Неклюдова ПВ. Последовательная комбинированная терапия у больной идиопатической легочной артериальной гипертензией. Кардиология, 2016, 56: 3.
9. Pepke-Zaba J, DeLcroix M, Lang I et aL. Chronic thromboemboLic puLmonary hypertension (CTEPH): resuLts from an internationaL prospective registry. Circulation, 2011, 124: 1973-1981.
10. Lang IM, Pesavento R, Bonderman D, Yuan JX. Risk factors and basic mechanisms of chronic throm-boemboLic puLmonary hypertension: a current understanding. Eur Respir J, 2013, 41: 462-468.
11. O'CaLLaghan Ds et aL. Treatment of puLmonary arteriaL hypertension with targeted therapies. Nat Rev Cardiol, 2011, 8: 526-538.
12. Государственный реестр лекарственных средств: http://grLs.rosminzdrav.ru.
13. Инструкция по медицинскому применению лекарственного препарата Опсамит ЛП-003310-161115. Доступна по ссылке: http//grLs.rosmin-zdrav.ru/GrLs_View_v2.aspx?idReg=1309913&t=.
14. Инструкция по медицинскому применению лекарственного препарата Адемпас. ЛП 002639250914. Доступна по ссылке: http://grLs.rosmin-zdrav.ru/GrLs_View_v2.aspx?idReg=86125&t=.
15. Инструкция по медицинскому применению лекарственного препарата Вентавис. ЛСР-005775/10-230610. Доступна по ссылке: http//grLs. rosminzdrav.ru/GrLs_View_v2.aspx?idReg=32487&t=.
16. Brigitta Badiani, Andrea Messori. Targeted Treatments for PuLmonary ArteriaL Hypertension: Interpreting Outcomes by Network Meta-anaLysis. Heart, Lung and Circulation, 2016,) 25: 46-52.
17. Taichman DB, OrneLas J, Chung L, KLinger JR, Lewis S, MandeL J et aL. PharmacoLogic therapy for puLmonary arteriaL hypertension in aduLts: CHEST guideLine and expert paneL report. Chest, 2014, 146(2): 449-75.
18. SuntharaLingam et aL. Long-term Use of SiLdenafiL in InoperabLe Chronic ThromboemboLic PuLmonary Hypertension. CHEST, 2008, 134: 229-236.
19. Jais X, D'Armini AM, Jansa P et aL. Bosentan for treatment of inoperabLe chronic thromboem-boLic puLmonary hypertension: BENEFiT (Bosentan Effects in iNopErabLe Forms of chronic ThromboemboLic puLmonary hypertension), a randomized, pLacebo-controLLed triaL. J Am Coll Cardiol, 2008, 52: 2127-134.
20. OLschewski H. et aL. InhaLed ILoprost For Severe PuLmonary Hypertnesion. N Engl J Med, 2002, 347: 322-9.
21. AMBER-I triaL. Ambrisentan for InoperabLe Chronic ThromboemboLic PuLmonary Hypertension. NCT01884675: https://cLinicaLtriaLs. gov/ct2/show/study/NCT01884675?sect=X70156.
22. MERIT-1 triaL. CLinicaL Study to Assess the Efficacy, Safety and ToLerabiLity of Macitentan in Subjects With InoperabLe Chronic ThromboemboLic PuLmonary Hypertension. NCT02021292: https://cLinicaLtriaLs.gov/ct2/ show/study/NCT02021292?view=resuLts.
23. WiLkins MR. PuLmonary hypertension: the science behind the disease spectrum. Eur Respir Rev, 2012, 21(123): 19-26.
24. Инструкция по медицинскому применению лекарственного препарата Ревацио. ЛП 000197130514. Доступна по ссылке: http//grLs.rosmin-zdrav.ru/GrLs_View_v2.aspx?idReg=1312767&t=.
25. Johannes-Peter Stasch et aL. SoLubLe GuanyLate CycLase as an Emerging Therapeutic Target in CardiopuLmonary Disease. Circulation, 2011, 123: 2263-2273.
26. Evgenov OV et aL. NO-independent stimuLators and activators of soLubLe guanyLate cycLase: discovery and therapeutic potentiaL. Nat Rev Drug Discov, 2006 September, 5(9): 755-768.
27. Ghofrani HA et aL. Riociguat for puLmonary hypertension. Future Cardiol, 2010, 6(2): 155-166.
28. Guha M. First-in-cLass guanyLate cycLase stimuLator approved for PAH. Nat Biotechnol 2013;31:1064. (doi:10.1038/nbt1213-1064b) AvaiLabLe on: http//www.nature.com/nbt/jour-naL/v31/n12/pdf/nbt1213-1064b.pdf.
29. Lewis J. Rubin et aL. Riociguat for the treatment of puLmonary arteriaL hypertension: a Long-term extension study (PATEnT-2). Eur Respir J 2015; 45: 1303-1313 (DOI: 10.1183/09031936.00090614) + SuppLementary materiaL (ONLINE SUPPLEMENTARY INFORMATION).
30. GeraLd Simonneau et aL. Riociguat for the treatment of chronic thromboemboLic puLmonary hypertension: a Long-term extension study (CHEST-2). ERJ May 1, 2015 voL. 45 no. 5 12931302. (ERJ Express. PubLished on November 13, 2014 as doi: 10.1183/09031936.00087114) + onLine suppLementary information
31. Lewis J Rubin, Nazzareno GaLie, Friedrich Grimminger, Ekkehard Grunig, Marc Humbert, Zhi-Cheng Jing, Anne Keogh, David LangLeben, Arno Fritsch, FLavia Menezes, NeiL Davie, Hossein-Ardeschir Ghofrani. Late-breaking abstract: Riociguat for the treatment of puLmonary arteriaL hypertension (PAH): 2-year resuLts from the PATENT-2 Long-term extension. European Respiratory Journal Sep, 2014, 44(SuppL 58). http:// erj.ersjournaLs.com/content/44/SuppL_58/P1803
32. GeraLd Simonneau, Andrea M. DArmini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Marius M. Hoeper, PaveL Jansa, Nick H. Kim, Chen Wang, Martin WiLkins, Arno Fritsch, NeiL Davie, PabLo CoLorado, Eckhard Mayer. Late-breaking abstract: Riociguat for the treatment of chronic thromboemboLic puLmonary hypertension (CTEPH): 2-year resuLts from the CHEST-2 Long-term extension. European Respiratory Journal, Sep 2014, 44(SuppL 58). Link: http//erj.ers-journaLs.com/content/44/SuppL_58/P1802.
33. Chazova I.E., Martynyuk T.V. (ed.). Pulmonary hypertension. М.: Practice 2015: 55-103.
34. Chazova I.E., Martynyuk T.V., Avdeev S.N., Volkov A.V., Nakonechnikov S.N. Clinical guidelines to the diagnosis and treatment of pulmonary hypertension. Evraziyskiy Kardiologicheskiy Zhurnal, 2014, 4: 4-23.
35. Tsareva N.A., Avdeev S.N., Neklyudova G.V. Sequential combination therapy in a female patient with idiopathic pulmonary arterial hypertension. Kardiologiya, 2016, 56: 3.
36. State register of medicines; http://grls.rosminzdrav.ru.
37. Opsumit: instruction for medical use. LP-003310-161115. Available at http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1309913&t=.
38. Adempas: instruction for medical use. LP 002639-250914. Available at http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=86125&t=.
39. Ventavis: instruction for medical use. LSR-005775/10-230610. Available at http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=32487&t=
40. Revatio: instruction for medical use. LP 000197-130514. Available at http://grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=1312767&t=
Рецензия
Для цитирования:
Царева Н.А., Авдеев С.Н. Риоцигуат - новый препарат для лечения легочной артериальной гипертензии и хронической тромбоэмболической легочной гипертензии. Медицинский Совет. 2016;(4):20-27. https://doi.org/10.21518/2079-701X-2016-4-20-27
For citation:
Tsareva N.A., Avdeev S.N. Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Meditsinskiy sovet = Medical Council. 2016;(4):20-27. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-20-27